Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines

Hentati-Kallel,Marwa; Le Jan,Sébastien; Bernard,Philippe; Antonicelli,Frank; Trussardi-Régnier,Aurélie

doi:10.3892/ijo.2016.3830

Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines

Authors:
- Marwa Hentati-Kallel
- Sébastien Le Jan
- Philippe Bernard
- Frank Antonicelli
- Aurélie Trussardi-Régnier
View Affiliations

Affiliations: EA7319 Derm-I-C, Health Center, University of Reims-Champagne-Ardenne, 51096 Reims, France
Published online on: December 30, 2016 https://doi.org/10.3892/ijo.2016.3830
Pages: 717-726

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucocorticoids are largely used in the treatment of inflammatory pathologies and/or hematological malignancies and regulate the expression of a variety of genes involved in inflammation or metastasis such as matrix metalloproteinases (MMP). Long-term exposure to glucocorticoids can result in failure of responsiveness, which is often associated with an unwanted gene expression. Epigenetic mechanisms are involved in gene expression modulated after development of glucocorticoid resistance but how these mechanisms take place must be further studied. The effects of HDAC inhibitors (HDACi) in a context of glucocorticoid resistance are still not well understood and need to be further investigated. We hypothesized that acquired glucocorticoid resistance associated to HDACi could disturbs epigenetic landscape, especially miR expression, leading to a modulation of MMP-9 gene expression and/or protein secretion, described as largely involved in bone remodeling and tumor invasion in multiple myeloma. To this aim, we used sensitive RPMI-8226 cell line and its dexamethasone- and methylprednisolone-resistant derivatives. The resistant cell lines displayed an ‘open chromatin’ and an MMP-9 overexpression comparatively to the sensitive cell line. HDACi treatment with MS-275 increased even more MMP-9 overexpression not only at an mRNA level but also at the protein level. We showed that MMP-9 expression regulation was not directly linked with HAT/HDAC balance alterations but rather with the deregulation of MMP-9-targeting miRs. Then, we first demonstrated that miR‑149 downregulation was directly involved in the MMP-9 overexpression following a chronic glucocorticoid exposure and that MS-275 could amplify this overexpression by inhibition of miR‑149 expression and miR‑520c overexpression. Taken together, these results indicate that the use of HDACi in a context of acquired glucocorticoid resistance could modify the epigenetic landscape, highlighting the importance of taking the glucocorticoid response status into consideration in treatment with HDACi.

View Figures

View References

1	Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Michel C, Jegou J, Grange F, et al: Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: A multicenter, prospective study. JAMA Dermatol. 150:25–33. 2014. View Article : Google Scholar
2	Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, et al: Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 126:2284–2290. 2015. View Article : Google Scholar : PubMed/NCBI
3	Pufall MA: Glucocorticoids and cancer. Adv Exp Med Biol. 872:315–333. 2015. View Article : Google Scholar : PubMed/NCBI
4	Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q and Cortijo J: Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 134:314–322. 2014. View Article : Google Scholar : PubMed/NCBI
5	Schmidt S, Rainer J, Ploner C, Presul E, Riml S and Kofler R: Glucocorticoid-induced apoptosis and glucocorticoid resistance: Molecular mechanisms and clinical relevance. Cell Death Differ. 11(Suppl 1): S45–S55. 2004. View Article : Google Scholar : PubMed/NCBI
6	Barnes PJ: Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 120:76–85. 2010. View Article : Google Scholar : PubMed/NCBI
7	Vandooren J, Opdenakker G, Loadman PM and Edwards DR: Proteases in cancer drug delivery. Adv Drug Deliv Rev. 97:144–155. 2016. View Article : Google Scholar : PubMed/NCBI
8	Poplineau M, Doliwa C, Schnekenburger M, Antonicelli F, Diederich M, Trussardi-Régnier A and Dufer J: Epigenetically induced changes in nuclear textural patterns and gelatinase expression in human fibrosarcoma cells. Cell Prolif. 46:127–136. 2013. View Article : Google Scholar : PubMed/NCBI
9	Poplineau M, Schnekenburger M, Dufer J, Kosciarz A, Brassart-Pasco S, Antonicelli F, Diederich M and Trussardi-Régnier A: The DNA hypomethylating agent, 5-aza-2′-deoxycytidine, enhances tumor cell invasion through a transcription-dependent modulation of MMP-1 expression in human fibrosarcoma cells. Mol Carcinog. 54:24–34. 2015. View Article : Google Scholar
10	Nicolaides NC, Galata Z, Kino T, Chrousos GP and Charmandari E: The human glucocorticoid receptor: Molecular basis of biologic function. Steroids. 75:1–12. 2010. View Article : Google Scholar :
11	Ishiguro H, Kawahara T, Zheng Y, Kashiwagi E, Li Y and Miyamoto H: Differential regulation of bladder cancer growth by various glucocorticoids: Corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Cancer Chemother Pharmacol. 74:249–255. 2014. View Article : Google Scholar : PubMed/NCBI
12	González-Muniesa P, Marrades MP, Martínez JA and Moreno-Aliaga MJ: Differential proinflammatory and oxidative stress response and vulnerability to metabolic syndrome in habitual high-fat young male consumers putatively predisposed by their genetic background. Int J Mol Sci. 14:17238–17255. 2013. View Article : Google Scholar : PubMed/NCBI
13	Park C-S, Lee YS, Kwon H-S, Lee T, Kim TB, Moon KA, Yoo B, Moon HB and Cho YS: Chlamydophila pneumoniae inhibits corticosteroid-induced suppression of metalloproteinase-9 and tissue inhibitor metalloproteinase-1 secretion by human peripheral blood mononuclear cells. J Med Microbiol. 61:705–711. 2012. View Article : Google Scholar : PubMed/NCBI
14	Jung SH, Wang Y, Kim T, Tarr A, Reader B, Powell N and Sheridan JF: Molecular mechanisms of repeated social defeat-induced glucocorticoid resistance: Role of microRNA. Brain Behav Immun. 44:195–206. 2015. View Article : Google Scholar
15	Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, et al: Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 116:3013–3022. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wang W, Li JJ, Foster PS, Hansbro PM and Yang M: Potential therapeutic targets for steroid-resistant asthma. Curr Drug Targets. 11:957–970. 2010. View Article : Google Scholar : PubMed/NCBI
17	Barnes PJ: Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 131:636–645. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ and Ito K: A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol. 169:1024–1034. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ and Adcock IM: Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 203:7–13. 2006. View Article : Google Scholar
20	Barnes PJ, Adcock IM and Ito K: Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur Respir J. 25:552–563. 2005. View Article : Google Scholar : PubMed/NCBI
21	Poplineau M, Dufer J, Antonicelli F and Trussardi-Regnier A: Epigenetic regulation of proMMP-1 expression in the HT1080 human fibrosarcoma cell line. Int J Oncol. 38:1713–1718. 2011.PubMed/NCBI
22	Frank A, David V, Aurelie T-R, Florent G, William H and Philippe B: Regulation of MMPs during melanoma progression: From genetic to epigenetic. Anticancer Agents Med Chem. 12:773–782. 2012. View Article : Google Scholar : PubMed/NCBI
23	Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P and Gronemeyer H: HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol. 39:1500–1509. 2007. View Article : Google Scholar : PubMed/NCBI
24	Barillé S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R and Amiot M: Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 90:1649–1655. 1997.PubMed/NCBI
25	Kelly T, Børset M, Abe E, Gaddy-Kurten D and Sanderson RD: Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma. 37:273–281. 2000.PubMed/NCBI
26	Urbaniak-Kujda D, Kapelko-Slowik K, Prajs I, Dybko J, Wolowiec D, Biernat M, Slowik M and Kuliczkowski K: Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma. Hematology. 21:26–33. 2016. View Article : Google Scholar
27	Redic KA, Hough SM and Price EM: Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: Impact of panobinostat, the first-in-class histone deacetylase inhibitor. Onco Targets Ther. 9:2783–2793. 2016. View Article : Google Scholar : PubMed/NCBI
28	Tandon N, Ramakrishnan V and Kumar SK: Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin Pharmacol. 8:35–44. 2016.PubMed/NCBI
29	Cai B, Lyu H, Huang J, Wang S, Lee C-K, Gao C and Liu B: Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Lett. 335:343–350. 2013. View Article : Google Scholar : PubMed/NCBI
30	Yang A, Ma J, Wu M, Qin W, Zhao B, Shi Y, Jin Y and Xie Y: Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies. Leuk Lymphoma. 53:2465–2473. 2012. View Article : Google Scholar : PubMed/NCBI
31	Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, Armstrong SA and Lodish HF: miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood. 114:4169–4178. 2009. View Article : Google Scholar : PubMed/NCBI
32	Li G, Bu J, Zhu Y, Xiao X, Liang Z and Zhang R: Curcumin improves bone microarchitecture in glucocorticoid-induced secondary osteoporosis mice through the activation of microRNA-365 via regulating MMP-9. Int J Clin Exp Pathol. 8:15684–15695. 2015.
33	Genty V, Dine G and Dufer J: Phenotypical alterations induced by glucocorticoids resistance in RPMI-8226 human myeloma cells. Leuk Res. 28:307–313. 2004. View Article : Google Scholar
34	Genty V, El-Khoury V, Liautaud-Roger F, Dine G and Dufer J: Nuclear chromatin patterns in 3 glucocorticoid-resistant RPMI-8226 human myeloma cell sub-lines: Correlations with cell growth and immunological phenotype. Cancer Biol Ther. 4:832–839. 2005. View Article : Google Scholar : PubMed/NCBI
35	Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
36	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
37	Debret R, Le Naour RR, Sallenave J-M, Deshorgue A, Hornebeck WG, Guenounou M, Bernard P and Antonicelli FD: Elastin fragments induce IL-1beta upregulation via NF-kappaB pathway in melanoma cells. J Invest Dermatol. 126:1860–1868. 2006. View Article : Google Scholar : PubMed/NCBI
38	Randall MJ, Haenen GRMM, Bouwman FG, van der Vliet A and Bast A: The tobacco smoke component acrolein induces glucocorticoid resistant gene expression via inhibition of histone deacetylase. Toxicol Lett. 240:43–49. 2016. View Article : Google Scholar :
39	Adcock IM, Ito K and Barnes PJ: Glucocorticoids: Effects on gene transcription. Proc Am Thorac Soc. 1:247–254. 2004. View Article : Google Scholar
40	Ma P, Pan H, Montgomery RL, Olson EN and Schultz RM: Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development. Proc Natl Acad Sci USA. 109:E481–E489. 2012. View Article : Google Scholar : PubMed/NCBI
41	Karius T, Schnekenburger M, Dicato M and Diederich M: MicroRNAs in cancer management and their modulation by dietary agents. Biochem Pharmacol. 83:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
42	Trécul A, Morceau F, Gaigneaux A, Schnekenburger M, Dicato M and Diederich M: Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochem Pharmacol. 92:299–311. 2014. View Article : Google Scholar : PubMed/NCBI
43	Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
44	Palmieri D, Capponi S, Geroldi A, Mura M, Mandich P and Palombo D: TNFα induces the expression of genes associated with endothelial dysfunction through p38MAPK-mediated downregulation of miR-149. Biochem Biophys Res Commun. 443:246–251. 2014. View Article : Google Scholar
45	Liu P and Wilson MJ: miR-520c and miR-373 upregulate MMP-9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells. J Cell Physiol. 227:867–876. 2012. View Article : Google Scholar
46	Zhou Y, Li Y, Ye J, Jiang R, Yan H, Yang X, Liu Q and Zhang J: MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition. Liver Int. 33:1271–1280. 2013. View Article : Google Scholar : PubMed/NCBI
47	Ucar A, Vafaizadeh V, Jarry H, Fiedler J, Klemmt PA, Thum T, Groner B and Chowdhury K: miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat Genet. 42:1101–1108. 2010. View Article : Google Scholar : PubMed/NCBI
48	Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, et al: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 10:202–210. 2008. View Article : Google Scholar : PubMed/NCBI
49	Yang K, Handorean AM and Iczkowski KA: MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol. 2:361–369. 2009.PubMed/NCBI